Helen A Petousis-Harris

List of Publications by Year
in descending order

58	1,223	430874 18	395702 33
papers	citations	h-index	g-index

59	59	59	1428
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Influences on Pregnant Womenâ€™s and Health Care Professionalsâ€™ Behaviour Regarding Maternal Vaccinations: A Qualitative Interview Study. Vaccines, 2022, 10, 76.	4.4	15
2	Increasing Uptake of Maternal Pertussis Vaccinations through Funded Administration in Community Pharmacies. Vaccines, 2022, 10, 150.	4.4	9
3	An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australiaâ€"Study Protocol. Vaccines, 2022, 10, 309.	4.4	3
4	Recommendation to take a holistic view of the dynamic pathogenic pneumococcal environment. Clinical Infectious Diseases, 2022, , .	5.8	1
5	Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions. BMJ Global Health, 2021, 6, e003540.	4.7	8
6	Impact of rotavirus vaccine on paediatric rotavirus hospitalisation and intussusception in New Zealand: A retrospective cohort study. Vaccine, 2020, 38, 1730-1739.	3.8	4
7	Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Safety, 2020, 43, 1205-1210.	3.2	34
8	Impact of antivaccination campaigns on health worldwide: lessons for Australia and the global community. Medical Journal of Australia, 2020, 213, 300.	1.7	1
9	Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine, 2020, 38, 4362-4373.	3.8	46
10	Global landscape analysis of no-fault compensation programmes for vaccine injuries: A review and survey of implementing countries. PLoS ONE, 2020, 15, e0233334.	2.5	27
11	A Qualitative Study of Views and Experiences of Women and Health Care Professionals about Free Maternal Vaccinations Administered at Community Pharmacies. Vaccines, 2020, 8, 152.	4.4	18
12	Progress Toward a Global Vaccine Data Network. Pediatric Infectious Disease Journal, 2020, 39, 1023-1025.	2.0	4
13	Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. New Zealand Medical Journal, 2020, 133, 112-118.	0.5	7
14	Pneumococcal Conjugate Vaccines Turning the Tide on Inequity: A Retrospective Cohort Study of New Zealand Children Born 2006â€"2015. Clinical Infectious Diseases, 2019, 68, 818-826.	5.8	16
15	Reply to â€œComment on Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study, Vaccines, 2019, 1, 5; doi:10.3390/vaccines7010005â€• Vaccines, 2019, 7, 32.	4.4	1
16	Pertussis Vaccination Failure in the New Zealand Pediatric Population: Study Protocol. Vaccines, 2019, 7, 65.	4.4	0
17	A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero. Vaccines, 2019, 7, 147.	4.4	12
18	Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines. Frontiers in Immunology, 2019, 10, 683.	4.8	30

#	Article	IF	Citations
19	Comparison of vaccination coverage of four childhood vaccines in New Zealand and New York State. Journal of Paediatrics and Child Health, 2019, 55, 781-788.	0.8	2
20	Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study. Vaccines, 2019, 7, 5.	4.4	43
21	Author reply to VA-MENGOC-BC cross-protection (2018HV0022). Human Vaccines and Immunotherapeutics, 2018, 14, 1069-1069.	3.3	0
22	Pitfalls of the healthy vaccinee effect â€“ Authors' reply. Lancet, The, 2018, 391, 123-124.	13.7	0
23	Impact of meningococcal group B OMV vaccines, beyond their brief. Human Vaccines and Immunotherapeutics, 2018, 14, 1058-1063.	3.3	46
24	Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine. Vaccine, 2018, 36, 5173-5179.	3.8	49
25	Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand. Vaccine, 2017, 35, 177-183.	3.8	19
26	Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet, The, 2017, 390, 1603-1610.	13.7	303
27	Infant outcomes after exposure to Tdap vaccine in pregnancy: an observational study. BMJ Open, 2016, 6, e009536.	1.9	50
28	Safety of Tdap vaccine in pregnant women: an observational study. BMJ Open, 2016, 6, e010911.	1.9	38
29	Cherry picked case reports are not scientific evidence in the face of large clinical and epidemiological studies. Clinical Rheumatology, 2016, 35, 837-838.	2.2	0
30	Proposed HPV vaccination syndrome is unsubstantiated. Clinical Rheumatology, 2016, 35, 833-834.	2.2	10
31	Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents. Human Vaccines and Immunotherapeutics, 2015, 11, 1872-1877.	3.3	10
32	An investigation of three injections techniques in reducing local injection pain with a human papillomavirus vaccine: A randomized trial. Vaccine, 2013, 31, 1157-1162.	3.8	12
33	Human papillomavirus vaccination in Auckland: Reducing ethnic and socioeconomic inequities. Vaccine, 2012, 31, 84-88.	3.8	16
34	Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: The importance of routine active safety surveillance. Vaccine, 2012, 30, 4945-4952.	3.8	21
35	Measuring disparities in immunisation coverage among children in New Zealand. Health and Place, 2012, 18, 1217-1223.	3.3	11
36	What contributes to delays? The primary care determinants of immunisation timeliness in New Zealand. Journal of Primary Health Care, 2012, 4, 12.	0.6	17

#	Article	IF	Citations
37	Early connections: effectiveness of a pre-call intervention to improve immunisation coverage and timeliness. Journal of Primary Health Care, 2012, 4, 189.	0.6	5
38	What contributes to delays? The primary care determinants of immunisation timeliness in New Zealand. Journal of Primary Health Care, 2012, 4, 12-20.	0.6	3
39	Fever following administration of two inactivated influenza vaccinesâ€"A survey of parents of New Zealand infants and children 5 years of age and under. Vaccine, 2011, 29, 2933-2937.	3.8	10
40	Back to Back: Saturated fat has been unfairly demonised: Yes. Journal of Primary Health Care, 2011, 3, 317.	0.6	3
41	Primary care practice and health professional determinants of immunisation coverage. Journal of Paediatrics and Child Health, 2011, 47, 541-549.	0.8	11
42	Saturated fat has been unfairly demonised: yes. Journal of Primary Health Care, 2011, 3, 317-9.	0.6	0
43	Fact or fallacy? Immunisation arguments in the New Zealand print media. Australian and New Zealand Journal of Public Health, 2010, 34, 521-526.	1.8	7
44	Factors associated with immunisation coverage and timeliness in New Zealand. British Journal of General Practice, 2010, 60, e113-e120.	1.4	24
45	Immunization champions: Characteristics of general practitioners associated with better immunization delivery. Hum Vaccin, 2009, 5, 403-411.	2.4	6
46	Seize the moments: missed opportunities to immunize at the family practice level. Family Practice, 2009, 26, 275-278.	1.9	19
47	Recruitment of practices in primary care research: the long and the short of it. Family Practice, 2009, 26, 128-136.	1.9	43
48	The cost of immunising at the general practice level. Journal of Primary Health Care, 2009, 1, 286.	0.6	8
49	The use and misuse of media headlines: lessons from the MeNZB immunisation campaign. New Zealand Medical Journal, 2009, 122, 22-7.	0.5	6
50	Determining immunisation coverage rates in primary health care practices: A simple goal but a complex task. International Journal of Medical Informatics, 2008, 77, 477-485.	3.3	12
51	Vaccine injection technique and reactogenicityâ€"Evidence for practice. Vaccine, 2008, 26, 6299-6304.	3.8	53
52	MeNZBâ„¢ vaccine and epidemic control: When do you stop vaccinating?. Vaccine, 2008, 26, 5899-5904.	3.8	17
53	Immunization in the Print Mediaâ€"Perspectives Presented by the Press. Journal of Health Communication, 2007, 12, 759-770.	2.4	16
54	Follow-up of MMR Vaccination Status in Children Referred to a Pediatric Immunization Clinic on Account of Egg Allergy. Hum Vaccin, 2005, 1, 118-122.	2.4	12

#	Article	IF	Citations
55	Family practice nurse views on barriers to immunising children. Vaccine, 2005, 23, 2725-2730.	3.8	39
56	The New Zealand national immunisation hotlineâ€"what are callers seeking?. Vaccine, 2005, 23, 5038-5044.	3.8	2
57	Family physician perspectives on barriers to childhood immunisation. Vaccine, 2004, 22, 2340-2344.	3.8	39
58	Needle angle when giving i.m. vaccinations. Nursing Praxis in New Zealand, 2002, 18, 52-3.	0.2	1